|Systematic (IUPAC) name|
|Mol. mass||373.486 g/mol|
Fedotozine (INN; Jo-1196) is an opioid drug of the arylacetamide series which acts as a peripherally-specific, selective κ1-opioid receptor agonist with preference for the κ1A subtype. It was under investigation for the treatment of gastrointestinal conditions like irritable bowel syndrome and functional dyspepsia and made it to phase III clinical trials, but ultimately development was discontinued and it was never marketed.
See also 
- Delvaux M (January 2001). "Pharmacology and clinical experience with fedotozine". Expert Opinion on Investigational Drugs 10 (1): 97–110. doi:10.1517/135437184.108.40.206. PMID 11116283.
- Barber A, Gottschlich R (October 1997). "Novel developments with selective, non-peptidic kappa-opioid receptor agonists". Expert Opinion on Investigational Drugs 6 (10): 1351–68. doi:10.1517/135437220.127.116.111. PMID 15989506.
- Lembo A (2006). "Peripheral opioids for functional GI disease: a reappraisal". Digestive Diseases (Basel, Switzerland) 24 (1-2): 91–8. doi:10.1159/000090312. PMID 16699267.